Dermalyser
Overview
Dermalyser is an AI-powered decision support app designed for medical professionals to obtain a second opinion on skin lesions. It is clinically validated for accurate assessments, boasting a 96% accuracy (AUC) in evaluating skin lesions. The tool is a CE-marked medical device, compliant with EU MDR 2017/745, signifying its adherence to European medical device regulations.
The app aims to facilitate faster diagnoses, reduce unnecessary procedures, and provide greater peace of mind in clinical decisions. It functions by analyzing a dermatoscopic image captured with a smartphone, delivering AI-driven decision support in seconds. Dermalyser demonstrates 95% sensitivity and 85% specificity in melanoma detection, along with a 99.5% Negative Predictive Value (NPV) when ruling out malignancy for benign lesions.
Developed in collaboration with dermatologists and primary care physicians, Dermalyser supports a range of medical professionals including Primary Care Physicians, Dermatologists, and General Practitioners. It is designed to be an assistant, not a replacement, ensuring that the final diagnosis always remains with the healthcare professional.
The use of Dermalyser can lead to significant operational benefits, including potential 56% cost savings and a 79% reduction in unnecessary referrals, by enabling more accurate assessments and reducing overtreatment.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered decision support for skin lesions
- 96% accuracy (AUC) in assessing skin lesions
- CE-marked medical device (EU MDR 2017/745, Class IIa)
- 95% sensitivity and 85% specificity in melanoma detection
- 99.5% Negative Predictive Value (NPV) for benign lesions
- 5-second analysis time
- Smartphone-based dermatoscopic image analysis
- Reduces unnecessary referrals (79% fewer)
- Potential for 56% cost savings
- Validated for Fitzpatrick skin types Iu2013IV
Use Cases
- Providing a second opinion on suspected skin melanomas
- Supporting primary care physicians and general practitioners in skin cancer diagnosis
- Assisting dermatologists with rapid, AI-driven analysis
- Reducing unnecessary referrals to dermatology specialists
- Improving diagnostic accuracy and confidence at the point of care
- Streamlining clinical workflow for skin lesion examination
What Physicians Need to Know
Dermalyser serves as a powerful decision-support tool, particularly valuable in primary care for initial melanoma screening and guiding referral decisions, and for dermatologists seeking a rapid second opinion. Remember, it's an assistant, not a replacement for your clinical judgment; the final diagnosis is always yours. Be mindful of its validated scope: it's intended for suspected melanomas on Fitzpatrick skin types I-IV and has specific contraindications (e.g., not for patients under 18, ulcerated lesions, or lesions outside 2mm-2cm). Leveraging this tool can enhance diagnostic confidence, streamline patient pathways, and contribute to significant cost savings by reducing unnecessary procedures.
Dermalyser primarily integrates as a smartphone application, requiring a compatible dermatoscope to capture images. For healthcare systems looking for deeper integration, the DermAIM AI engine is available via secure APIs, allowing vendors to embed its clinically validated skin lesion risk assessment capabilities directly into their existing platforms.
Details
| Category | Dermatology AI, Oncology AI |
| Pricing | Contact for details |
| Deployment | Cloud-based |
| Compliance | |
| BAA Available | No AI-estimated |
| HIPAA Compliant | No AI-estimated |
| FDA Status |
No AI-estimated Dermalyser is CE-marked under MDR (EU) 2017/745 as a Class IIa medical device software, enabling its commercial use across Europe. A US launch is anticipated in 2027 pending FDA 510(k) clearance. |
| Integrations | |
| EHR | Not specified |
| Specialties | Dermatology, Family Medicine, Oncology |
What the Web Says
Dermalyser is an AI-powered medical device software designed to assist healthcare professionals in the assessment of skin lesions, specifically for melanoma risk evaluation. It analyzes dermatoscopic images captured via a compatible dermatoscope attached to an iPhone, providing real-time, AI-driven assessments. Clinical studies have shown Dermalyser to have high diagnostic accuracy, often outperforming expert dermatologists and general practitioners in detecting melanoma.
Overall: PositiveStrengths
- Clinically validated performance with high accuracy (AUC score of 0.96), surpassing expert dermatologists (0.85) and general practitioners (0.70).
- Provides decision support in seconds, offering instant AI-powered assessments.
- Improves cost efficiency by helping reduce unnecessary skin excisions and streamlining clinical workflows.
- High sensitivity (95.2%) and specificity (84.5%) in detecting melanoma, with even higher rates for invasive melanomas (100% sensitivity and 92.6% specificity).
- Designed for healthcare professionals, developed with quality-controlled dermatoscopic images and patient data.
- High negative predictive value (99.5%), providing confidence in ruling out malignancy when a lesion is assessed as benign.
Limitations
- Intended only for suspected melanomas and should not be used on certain types of lesions (ulcerated, very large, on mucous membranes, under nails, on palms/soles, near eyes, or previously biopsied).
- Currently available only for iPhone.
- Limited information available from independent tech reviewers, G2, or Capterra.
- Some general Reddit discussions about AI in dermatology express concerns about potential for misdiagnosis if not used responsibly, or patients delaying care by relying solely on AI tools.
Based on reviews from: App Store (Apple), PR Newswire, AI Medical Technology official website, Canada Newswire, British Journal of Dermatology (via AI Support Tool Demonstrates Detection Utility for Melanoma at Primary Care Practices), Reddit
Last updated: 2026-07-31
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Dermalyser
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for Dermalyser.
Doximity AI: Medical AI With Real Physician Oversight
